BioCryst Pharmaceuticals (BCRX) Stock: Declining On Poor Trial Results

BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) BioCryst Pharmaceuticals is having an incredibly hard time in the market at the moment as the result of a recent release of clinical trial results. Unfortunately, a trial has shown that one of the company’s lead candidates is ineffective. Today, we’ll take a look at the trial results, how the … Read more